News Sentiment

TENX sentiment intelligence

Tenax Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 17.55 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

77/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

+13.5% over one week, +52.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Basic earnings per share (basic EPS) of Tenax Therapeutics, Inc. – TRADEGATE:YBO0

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 77/100 classification
One-week reaction 13.5% Price confirming higher
Trend fit Trend active 52.9% over four weeks
Fair value 76.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 9
Stock Titan 8
Market source 7
GlobeNewswire 5
Seeking Alpha 3
Investing News Network 3
simplywall.st 3
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 17
Deals and strategy 4
Regulatory and legal 3
Analyst action 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
TradingView Direct company coverage

Basic earnings per share (basic EPS) of Tenax Therapeutics, Inc. – TRADEGATE:YBO0

This article focuses on the basic earnings per share (basic EPS) for Tenax Therapeutics, Inc., traded on the Tradegate Exchange under the symbol YBO0. It appears to be a stub or a section within a larger financial data platform, providing a heading for EPS information without pre

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 05:39
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Tenax Therapeutics Inc For: 14 July By Investing.com

This article reports on a Form 4 filing for Tenax Therapeutics Inc (TENX) for transactions made on July 14. The company's stock symbol is TENX, and it experienced a -1.41% change. The main content of the article is the announcement of this regulatory filing.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
15 Jul 2026 11:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Tenax Therapeutics (TENX) CEO exercises options, adds 8,719 shares

Tenax Therapeutics, Inc. CEO Christopher Thomas Giordano exercised stock options on July 13, 2026, acquiring 8,719 common shares. These shares were purchased at exercise prices of $5.94 and $3.549 per share, with the aggregate exercise price paid in cash. Following these transact

Tone
Neutral 50/100
Event
Balance sheet
Published
14 Jul 2026 23:11
Source
Stock Titan
Stock Traders Daily Direct company coverage

(TENX) as a Liquidity Pulse for Institutional Tactics

An AI model analysis by Stock Traders Daily indicates a strong overweight bias for Tenax Therapeutics Inc. (NASDAQ: TENX) due to strong sentiment across all horizons and a mid-channel oscillation pattern. The analysis highlights an exceptional 89.3:1 risk-reward setup, targeting

Tone
Positive 74/100
Event
Balance sheet
Published
13 Jul 2026 16:41
Source
Stock Traders Daily
The Globe and Mail Direct company coverage

Tenax Therapeutics (TENX) Gets a Buy from LifeSci Capital

LifeSci Capital analyst Gaurav Maini has reiterated a Buy rating for Tenax Therapeutics (TENX) with a $35.00 price target. Maini is noted for his strong performance in the Healthcare sector. The broader analyst consensus for Tenax Therapeutics is a Strong Buy with an average pric

Tone
Positive 70/100
Event
Analyst action
Published
13 Jul 2026 11:39
Source
The Globe and Mail
Stock Titan Direct company coverage

FMR LLC reports 3.94M-share holding in Tenax Therapeutics (TENX)

FMR LLC has reported a 14.9% stake in Tenax Therapeutics (TENX), owning 3,942,373 shares of common stock as of June 30, 2026. This disclosure was made via a Schedule 13G filing, indicating a passive investment. The filing also notes sole dispositive power over these shares and re

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 14:39
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to EBITDA forward of Tenax Therapeutics, Inc. – NASDAQ:TENX

The article focuses on the enterprise value to EBITDA forward for Tenax Therapeutics, Inc. (NASDAQ: TENX). It presents a financial metric from TradingView, indicating a key valuation ratio for the company without providing specific numerical data. The content primarily serves as

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 23:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Tenax Therapeutics, Inc. – NASDAQ:TENX

This page from TradingView provides financial information for Tenax Therapeutics, Inc. (NASDAQ: TENX), specifically focusing on its price to earnings forward. The content indicates market and financial data, but the core numerical values are not displayed in this excerpt.

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 11:11
Source
TradingView
Moomoo Direct company coverage

LifeSci Capital Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Raises Target Price to $35

LifeSci Capital has maintained its "Buy" rating for Tenax Therapeutics (TENX.US) and increased its target price from $27 to $35. Analyst Gaurav Maini, who has a 100% success rate and a 31.8% average return over the past year, made this adjustment. This information is provided by

Tone
Positive 72/100
Event
Analyst action
Published
06 Jul 2026 12:41
Source
Moomoo
TradingView Direct company coverage

Price to sales forward of Tenax Therapeutics, Inc. – NASDAQ:TENX

This article displays financial data for Tenax Therapeutics, Inc. (NASDAQ: TENX), specifically focusing on its "Price to sales forward" metric. The content provides a snapshot of the company's financials and general market information through a TradingView interface.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 12:41
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Tenax Therapeutics, Inc. – NASDAQ:TENX

The article provides a title indicating an analysis of Tenax Therapeutics, Inc.'s enterprise value to EBIT forward. However, the content primarily consists of navigation links, market data disclaimers, and website information from TradingView, rather than a substantive financial

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 04:11
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Tenax Therapeutics, Inc. – LS:A3EVQN

This page provides financial data on Tenax Therapeutics, Inc. (A3EVQN), specifically focusing on its price-to-sales forward ratio. The content indicates that the market was closed at the time of viewing, with no trades reported. It also details the various data providers and copy

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 18:10
Source
TradingView
Market source Direct company coverage

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tenax Therapeutics announced inducement option awards on July 1, 2026, to three new non-executive employees in various roles, granting them non-qualified stock options to purchase 160,000 shares. These awards, approved by the Compensation Committee, serve as material inducements

Tone
Positive 63/100
Event
Market update
Published
03 Jul 2026 08:41
Source
Market source
Moomoo Direct company coverage

Tenax Therapeutics Is Maintained at Buy by Chardan Capital

Chardan Capital has reiterated its Buy rating on Tenax Therapeutics (NASDAQ: TENX). The article does not provide a price target or an updated analysis, only confirming the maintenance of the rating.

Tone
Positive 72/100
Event
Analyst action
Published
02 Jul 2026 19:10
Source
Moomoo
Investing News Network Direct company coverage

Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026

Tenax Therapeutics (Nasdaq: TENX) has announced that results from its Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich. The company expects to report topline LEVEL result

Tone
Positive 67/100
Event
Earnings
Published
02 Jul 2026 16:11
Source
Investing News Network
Stock Titan Direct company coverage

Late-breaking ESC 2026 spot for Tenax (TENX) Phase 3 LEVEL trial data

Tenax Therapeutics (TENX) announced that results from its Phase 3 LEVEL clinical trial for TNX-103 in pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) will be presented at the European Society of Cardiology Congress 2026 as a Late-Breaking Clini

Tone
Positive 66/100
Event
Earnings
Published
02 Jul 2026 12:09
Source
Stock Titan
Bitget Direct company coverage

Tenax Therapeutics, Inc. (TENX) announced that the data report from one of its pivotal clinical trials has been selected as a late-breaking presentation at the 2026 European Society of Cardiology Congress.

Tenax Therapeutics, Inc. (TENX) announced that a data report from one of its pivotal clinical trials has been selected as a late-breaking presentation at the 2026 European Society of Cardiology Congress. This selection indicates international recognition of the company's progress

Tone
Positive 72/100
Event
Market update
Published
02 Jul 2026 11:09
Source
Bitget
Stock Titan Direct company coverage

Tenax to present LEVEL trial data at ESC Congress before August results

Tenax Therapeutics (Nasdaq: TENX) will present Phase 3 LEVEL clinical trial results at the ESC Congress 2026 in Munich, Germany, on August 29, 2026. The trial focuses on TNX-103 (oral levosimendan) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-H

Tone
Positive 64/100
Event
Earnings
Published
02 Jul 2026 11:09
Source
Stock Titan
Stock Titan Direct company coverage

Tenax Therapeutics (NASDAQ: TENX) deepens Orion deal, extends approval deadline to 2035

Tenax Therapeutics has entered into a new Supply Agreement with Orion Corporation, making Orion responsible for manufacturing and supplying Tenax’s orally administered levosimendan product for development and commercial use. Concurrently, the companies signed a Sixth Amendment to

Tone
Positive 60/100
Event
Deals and strategy
Published
01 Jul 2026 06:10
Source
Stock Titan
Bitget Direct company coverage

Tenax Therapeutics, Inc. has extended the deadline for U.S. regulatory approval to December 31, 2035, through the sixth amendment to its licensing agreement with Orion.

Tenax Therapeutics, Inc. has extended the deadline for U.S. regulatory approval to December 31, 2035. This extension was facilitated through the sixth amendment to its licensing agreement with Orion. The postponement has been officially filed with the U.S. Securities and Exchange

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Jun 2026 21:10
Source
Bitget